# Palo Alto Investors

> Palo Alto Investors is a VC fund backing Health Care and Biotechnology. See 18 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 18
- Last investment: Sep 2025
- Lead investor: 6%
- Last updated: Aug 2026
- Website: http://www.pa-investors.com

Palo Alto Investors is an investment advisory company that provides money management services. It also operates as a private investment firm that offers long-term investments for high-net-worth and institutional investors based on original and fundamental research. Palo Alto Investors was founded in 1989 and is based in Palo Alto, California.

## Contacts

5 contacts available for Palo Alto Investors. Shizune tracks 8 team members at Palo Alto Investors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/palo-alto-investors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 50% |
| Biotechnology | 8 | 44% |
| Medical | 4 | 22% |
| Therapeutics | 4 | 22% |
| Biopharma | 2 | 11% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 5 | 28% |
| Post-IPO Equity | 4 | 22% |
| Series B | 2 | 11% |
| Series C | 2 | 11% |
| Funding Round | 2 | 11% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Doux | Managing Director | 1 | — |
| Alvin Tam | Head Trader | 0 | — |
| Charles Cho | Managing Director | 0 | — |
| Jennifer Trailer | Head of Operations & Office Manager | 0 | — |
| Joon Yun | Co-Managing Member & President | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Oruka Therapeutics | Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases. | $180M | Post-IPO Equity | Sep 17, 2025 |  |
| VYNE Therapeutics | VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chroniccough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20. | $88M | Post-IPO Equity | Oct 30, 2023 |  |
| Peak Bio | Peak Bio is a Biopharmaceutical company that focuses on the drug development to treat Oncology and Inflammatory diseases. | $25M | Post-IPO Equity | Apr 28, 2022 |  |
| NeXeption | NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships toadvance products for the benefit of patients. | $21.5M | Series A | Jan 02, 2014 |  |
| Ceptaris Therapeutics | Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topicalmechlorethamine product available to treat the signs and symptoms of this rare cancer. | $10M | Series D | Jun 05, 2012 |  |
| Ceptaris Therapeutics | Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topicalmechlorethamine product available to treat the signs and symptoms of this rare cancer. | $14.4M | Series D | Aug 11, 2011 |  |
| Fisker Automotive | Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to thebankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group. | $150M | Private Equity | Feb 22, 2011 |  |
| Fisker Automotive | Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to thebankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group. | $65M | Series C | Sep 09, 2008 |  |
| Fisker Automotive | Fisker Automotive was an American company known for producing the Fisker Karma, which was one of the world's first production luxury plug-in hybrid electric vehicles. It debuted at the 2008 North American International Auto Show, and the first deliveries were in 2011. Production of the Fisker Karma was suspended in November 2012 due to thebankruptcy of its battery supplier A123 Systems, with about 2,450 Karmas built since 2011 and over 2000 cars sold worldwide. In February 2014, Fisker Automotive's Karma vehicle design, tooling, and a manufacturing facility in Delaware were purchased by Chinese auto parts conglomerate Wanxiang Group. | $20M | Series B | Jan 14, 2008 |  |
| Paracor Medical | Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognizedthat a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution. | $44M | Series D | Jun 29, 2007 |  |

10 of 18 investments shown.

## Co-investors
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together
- [CHL Medical Partners](https://shizune.co/investors/profile/chl-medical-partners) — VC Fund, 3 deals together
- [DeNovo Ventures](https://shizune.co/investors/profile/denovo-ventures) — VC Fund, 3 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 3 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together
- [Burrill & Company](https://shizune.co/investors/profile/burrill-co) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Palo Alto Investors invest in?

Palo Alto Investors invests primarily in Health Care, Biotechnology and Medical startups, most often at Series D and Post-IPO Equity stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Palo Alto Investors?

Public channels for Palo Alto Investors include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Palo Alto Investors?

The team at Palo Alto Investors includes John Doux (Managing Director), Alvin Tam (Head Trader) and Charles Cho (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co